Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Blier

Showing results (201-210 of 229) with videos related to

Pageof 23
Sort By:
The International Journal of Neuropsychopharmacology|July 11, 2019
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)Maggie Fedgchin, Madhukar Trivedi, Ella J Daly, et al.
BMC Psychiatry|June 4, 2020
A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocolJennifer L Phillips, Natalia Jaworska, Elizabeth Kamler, et al.
Psychological Medicine|August 25, 2022
Prediction of depression treatment outcome from multimodal data: a CAN-BIND-1 reportMehri Sajjadian, Rudolf Uher, Keith Ho, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|August 4, 2016
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological TreatmentsSidney H Kennedy, Raymond W Lam, Roger S McIntyre, et al.
Journal of Affective Disorders|January 24, 2020
Reverse translation of major depressive disorder symptoms: A framework for the behavioural phenotyping of putative biomarkersStephen Daniels, Thomas Horman, Thomas Lapointe, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|December 26, 2025
Modulation of Brain Temporal Complexity During Treatment for Depression: A CAN-BIND-1 Study Report: Modulation de la complexité temporelle du cerveau pendant le traitement de la dépression: rapport de l'étude CAN-BIND-1Chloé Stengel, Benjamin Schwartzmann, Raaj Chatterjee, et al.
Biological Psychiatry. Cognitive Neuroscience and Neuroimaging|January 15, 2022
Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression StudyPrabhjot Dhami, Lena C Quilty, Benjamin Schwartzmann, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|November 11, 2020
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif MajeurJennifer Swainson, Alexander McGirr, Pierre Blier, et al.
Journal of Affective Disorders|November 24, 2017
The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot studyAnusha Baskaran, Faranak Farzan, Roumen Milev, et al.
Translational Psychiatry|September 6, 2022
Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 studyFarhana Islam, Victoria S Marshe, Leen Magarbeh, et al.
Pageof 23

Showing results (201-210 of 229) with videos related to

Sort By:
Pageof 23
The International Journal of Neuropsychopharmacology|July 11, 2019
Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)Maggie Fedgchin, Madhukar Trivedi, Ella J Daly, et al.
BMC Psychiatry|June 4, 2020
A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocolJennifer L Phillips, Natalia Jaworska, Elizabeth Kamler, et al.
Psychological Medicine|August 25, 2022
Prediction of depression treatment outcome from multimodal data: a CAN-BIND-1 reportMehri Sajjadian, Rudolf Uher, Keith Ho, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|August 4, 2016
Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological TreatmentsSidney H Kennedy, Raymond W Lam, Roger S McIntyre, et al.
Journal of Affective Disorders|January 24, 2020
Reverse translation of major depressive disorder symptoms: A framework for the behavioural phenotyping of putative biomarkersStephen Daniels, Thomas Horman, Thomas Lapointe, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|December 26, 2025
Modulation of Brain Temporal Complexity During Treatment for Depression: A CAN-BIND-1 Study Report: Modulation de la complexité temporelle du cerveau pendant le traitement de la dépression: rapport de l'étude CAN-BIND-1Chloé Stengel, Benjamin Schwartzmann, Raaj Chatterjee, et al.
Biological Psychiatry. Cognitive Neuroscience and Neuroimaging|January 15, 2022
Response Inhibition and Predicting Response to Pharmacological and Cognitive Behavioral Therapy Treatments for Major Depressive Disorder: A Canadian Biomarker Integration Network for Depression StudyPrabhjot Dhami, Lena C Quilty, Benjamin Schwartzmann, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|November 11, 2020
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif MajeurJennifer Swainson, Alexander McGirr, Pierre Blier, et al.
Journal of Affective Disorders|November 24, 2017
The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot studyAnusha Baskaran, Faranak Farzan, Roumen Milev, et al.
Translational Psychiatry|September 6, 2022
Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 studyFarhana Islam, Victoria S Marshe, Leen Magarbeh, et al.
Pageof 23